Janice Gabrilove

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
    J L Gabrilove
    Mount Sinai Medical Center, New York, NY 10029, USA
    J Clin Oncol 19:2875-82. 2001
  2. ncbi An analysis of current neutropenia therapies, including pegfilgrastim
    Janice L Gabrilove
    Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Cornerstone 8:S19-28. 2006
  3. ncbi Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
    Janice Gabrilove
    Department of Medicine, Mt Sinai School of Medicine, New York, NY 10029, USA
    Br J Haematol 142:379-93. 2008
  4. ncbi Anemia and the elderly: clinical considerations
    Janice Gabrilove
    Department of Medicine Division of Hematology, Medical Oncology, Mount Sinai School of Medicine, One Gustave L Levy Place, NY 10029, USA
    Best Pract Res Clin Haematol 18:417-22. 2005
  5. ncbi Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies
    J L Gabrilove
    Division of Medical Oncology, Department of Medicine, The Derald H Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029, USA
    Oncologist 6:4-7. 2001
  6. ncbi Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:4176-81. 2005
  7. ncbi Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks
    Janice L Gabrilove
    Division of Hematology Oncology, Mount Sinai Medical Center, New York, New York, USA
    Cancer 110:1629-40. 2007
  8. ncbi Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy
    Janice L Gabrilove
    J Clin Oncol 20:2757-8. 2002
  9. ncbi Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy
    George D Demetri
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 3:45-51. 2002
  10. ncbi Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006

Research Grants

  1. STRATEGIC CURRICULUM FOR CLINICAL RESEARCH
    Janice Gabrilove; Fiscal Year: 2004
  2. STRATEGIC CURRICULUM FOR CLINICAL RESEARCH
    Janice Gabrilove; Fiscal Year: 2007
  3. BP1 and Nuclear Hormone Signaling in Breast Cancer
    Janice Gabrilove; Fiscal Year: 2007

Detail Information

Publications10

  1. ncbi Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
    J L Gabrilove
    Mount Sinai Medical Center, New York, NY 10029, USA
    J Clin Oncol 19:2875-82. 2001
    ..To prospectively evaluate the effectiveness, safety, and clinical benefits of once-weekly epoetin alfa therapy as an adjunct to chemotherapy in anemic cancer patients...
  2. ncbi An analysis of current neutropenia therapies, including pegfilgrastim
    Janice L Gabrilove
    Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Cornerstone 8:S19-28. 2006
    ..Furthermore, the more convenient schedule of pegfilgrastim may be associated with greater treatment adherence and increased patient quality of life...
  3. ncbi Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
    Janice Gabrilove
    Department of Medicine, Mt Sinai School of Medicine, New York, NY 10029, USA
    Br J Haematol 142:379-93. 2008
    ..Thromboembolic or related adverse events occurred in 2% of patients; no pulmonary embolisms were reported. In conclusion, darbepoetin alfa, 500 microg Q3W appeared well tolerated and increased haemoglobin levels in low-risk MDS patients...
  4. ncbi Anemia and the elderly: clinical considerations
    Janice Gabrilove
    Department of Medicine Division of Hematology, Medical Oncology, Mount Sinai School of Medicine, One Gustave L Levy Place, NY 10029, USA
    Best Pract Res Clin Haematol 18:417-22. 2005
    ....
  5. ncbi Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies
    J L Gabrilove
    Division of Medical Oncology, Department of Medicine, The Derald H Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029, USA
    Oncologist 6:4-7. 2001
    ..Currently, a number of clinical trials are under way to evaluate the clinical potential of several different angiogenesis inhibitors in several hematologic neoplasms...
  6. ncbi Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:4176-81. 2005
    ..We sought to determine if flavopiridol has activity in previously treated CLL using two schedules of administration...
  7. ncbi Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks
    Janice L Gabrilove
    Division of Hematology Oncology, Mount Sinai Medical Center, New York, New York, USA
    Cancer 110:1629-40. 2007
    ....
  8. ncbi Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy
    Janice L Gabrilove
    J Clin Oncol 20:2757-8. 2002
  9. ncbi Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy
    George D Demetri
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 3:45-51. 2002
    ..3 times weekly). Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy...
  10. ncbi Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006
    ..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...

Research Grants4

  1. STRATEGIC CURRICULUM FOR CLINICAL RESEARCH
    Janice Gabrilove; Fiscal Year: 2004
    ..abstract_text> ..
  2. STRATEGIC CURRICULUM FOR CLINICAL RESEARCH
    Janice Gabrilove; Fiscal Year: 2007
    ..This award will continue to enable this Institution to foster and cultivate the educational horizons and growth of clinical scientists. ..
  3. BP1 and Nuclear Hormone Signaling in Breast Cancer
    Janice Gabrilove; Fiscal Year: 2007
    ..abstract_text> ..